08:12 AM EDT, 09/09/2024 (MT Newswires) -- Relay Therapeutics ( RLAY ) shares rose more than 12% premarket after the company reported Monday that patients who received RLY-2608 demonstrated clinically meaningful progression free survival with a median of 9.2 months despite heavy pre-treatment.

However, 25% of patients given RLY-2608 experienced Grade 3 treatment-related adverse events and two patients discontinued treatment.

The company plans to initiate dose expansion cohorts in first half of 2025.

Price: 7.05, Change: +0.81, Percent Change: +12.98